Peripheral Neuropathy in the Foot: All Causes Explained 2026

When patients come to our clinic with burning, tingling, or numb feet, the most important thing we do — before anything else — is ask why. Peripheral neuropathy is a symptom, not a diagnosis. It tells us that peripheral nerves are damaged or dysfunctioning; it doesn’t tell us the cause. And the cause matters enormously: neuropathy from B12 deficiency is reversible with supplementation; neuropathy from an uncontrolled autoimmune disease requires immunosuppression; hereditary neuropathy from Charcot-Marie-Tooth disease requires genetic counseling. Treating the burning feet without identifying the cause is missing the point.

How Peripheral Neuropathy Develops in the Foot

The peripheral nerves supplying the foot — the longest in the body — are vulnerable to a wide range of metabolic, toxic, immune, ischemic, and structural insults. Two patterns of injury explain most presentations: axonal neuropathy (the nerve fiber itself degenerates in a length-dependent, “dying-back” pattern from the toes upward — most common in metabolic and toxic causes) and demyelinating neuropathy (the myelin sheath is damaged, slowing conduction velocity while preserving axon integrity — more common in inflammatory and hereditary causes).

Both patterns produce a “stocking” distribution of symptoms in the feet: burning, tingling, numbness, or electric pain starting in the toes and ascending up the leg as the condition progresses. Axonal neuropathies first affect small fibers (C and Aδ fibers — pain and temperature), then large fibers (Aβ fibers — vibration and proprioception). This is why early neuropathy often has normal nerve conduction studies (NCS) — NCS only measures large-fiber conduction — while skin punch biopsy shows reduced intraepidermal nerve fiber density, the hallmark of small fiber neuropathy.

The Major Causes of Peripheral Neuropathy at a Glance

Diabetic Neuropathy

Diabetes mellitus is the most common identifiable cause of peripheral neuropathy in developed countries, responsible for approximately 30–50% of all cases. The mechanism involves chronic hyperglycemia activating multiple pathological pathways simultaneously — the polyol (sorbitol) pathway, advanced glycation end-product accumulation, oxidative stress, and endoneurial ischemia from microvascular disease. The result is a bilateral, symmetric, length-dependent sensorimotor neuropathy that begins in the toes and ascends up both legs proportional to the duration and severity of hyperglycemia.

Duration of diabetes is the strongest risk factor: 50% of Type 2 diabetics have measurable neuropathy after 25 years of disease. HbA1c level is the most modifiable driver — tight glycemic control (HbA1c below 7%) slows neuropathy progression in Type 1 diabetes and has more modest effects in Type 2. Coexisting risk factors — hypertension, dyslipidemia, smoking, alcohol — dramatically accelerate neuropathy in diabetics beyond what glycemia alone would predict.

Alcoholic Neuropathy

Chronic alcohol use disorder causes peripheral neuropathy through two distinct mechanisms: the direct neurotoxic effect of ethanol and its metabolite acetaldehyde on axonal transport and mitochondrial function, and nutritional deficiency — primarily thiamine (B1), but also B6, B12, and folate — from the combination of poor diet, malabsorption, and alcohol’s interference with B-vitamin metabolism. Thiamine deficiency alone produces a severe axonal sensorimotor neuropathy with painful burning feet, areflexia, and in advanced cases foot drop.

Alcoholic neuropathy is clinically significant because it can be partially reversed. Alcohol cessation combined with B-vitamin repletion (thiamine 100mg orally or IV, folate, B12) produces measurable improvement in intraepidermal nerve fiber density over 12–24 months in patients who achieve sustained abstinence. The painful small fiber symptoms often improve faster than large fiber deficits (vibration sense, proprioception). The key prognostic factor is whether abstinence can be maintained — continued alcohol use continues nerve damage that outpaces any recovery.

Vitamin B12 and Nutritional Deficiency Neuropathy

Vitamin B12 (cobalamin) deficiency is a critical and frequently underdiagnosed cause of peripheral neuropathy — crucial because it is fully reversible when caught early, and potentially irreversible if allowed to progress to established axonal loss. B12 is essential for myelin synthesis through the methionine cycle; deficiency disrupts myelin integrity first in the longest fibers (feet and lower legs) and in the posterior columns of the spinal cord (subacute combined degeneration).

The most important risk group in our patient population is metformin users. Metformin — the most commonly prescribed diabetes medication — blocks intestinal absorption of B12 via the ileal calcium-dependent transport mechanism. Studies show 10–30% of long-term metformin users have biochemical B12 deficiency, and this deficiency compounds diabetic neuropathy. Patients with diabetic neuropathy who take metformin should have serum B12 checked annually — a normal serum B12 (above 300 pg/mL) does not rule out functional deficiency; methylmalonic acid (MMA) and homocysteine levels are more sensitive markers of tissue-level B12 status.

Other high-risk groups: strict vegans (B12 is found only in animal products), patients with pernicious anemia (autoimmune gastric parietal cell destruction eliminates intrinsic factor), patients after gastric bypass surgery, chronic PPI users, and elderly patients (atrophic gastritis reduces intrinsic factor production). Supplementation with high-dose oral B12 (1,000mcg daily) or intramuscular injections reverses the neuropathy if axonal damage has not yet occurred.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is one of the most common dose-limiting side effects of cancer treatment, affecting 30–60% of patients depending on the chemotherapy regimen. The highest-risk agents are platinum compounds (cisplatin, oxaliplatin, carboplatin), taxanes (paclitaxel, docetaxel), vinca alkaloids (vincristine, vinblastine), and thalidomide/bortezomib. Each has a distinct mechanism: platinums form DNA adducts in dorsal root ganglion neurons; taxanes disrupt microtubule dynamics essential for axonal transport; vinca alkaloids depolymerize microtubules directly.

CIPN produces bilateral symmetric sensory neuropathy starting in the hands and feet simultaneously — distinguishing it from diabetic neuropathy, which starts in the feet first. Cold allodynia (pain from cold stimulation — touching a cold glass is painful) is characteristic of oxaliplatin neuropathy. CIPN often peaks during treatment then partially improves over months to years post-chemotherapy; some patients have permanent residual neuropathy. Duloxetine is the only agent with RCT evidence for CIPN treatment. Dose reduction or regimen change may be necessary in severe cases.

Uremic Neuropathy from Chronic Kidney Disease

Uremic neuropathy develops in advanced chronic kidney disease (CKD Stage 4–5, GFR below 30 mL/min) from the accumulation of uremic toxins — particularly methylguanidine and phenylacetic acid — that are directly neurotoxic to peripheral axons. It affects 60–90% of patients on long-term dialysis and presents as a bilateral burning, painful neuropathy in both feet, often combined with restless legs syndrome (an irresistible urge to move the legs at night — highly characteristic of uremic neuropathy).

Hemodialysis incompletely removes uremic toxins and only partially improves neuropathy. Renal transplantation with restoration of near-normal GFR produces the most significant improvement — nerve conduction studies show measurable recovery within months of successful transplant. From a podiatric perspective, uremic neuropathy patients also face impaired wound healing, immunosuppression from kidney disease and its treatments, and vascular disease — making diabetic-foot-equivalent vigilance appropriate even in non-diabetic CKD patients.

Autoimmune and Inflammatory Neuropathies

Several autoimmune diseases cause peripheral neuropathy through distinct mechanisms. Rheumatoid arthritis produces neuropathy through vasculitis of the vasa nervorum (the small vessels supplying peripheral nerves) — RA-related neuropathy can be mononeuritis multiplex (asymmetric, multifocal nerve damage) in addition to the typical symmetric pattern. Sjögren’s syndrome is particularly associated with a painful small fiber neuropathy and sensory ataxia from dorsal root ganglionopathy — often presenting without prominent sicca (dry eyes/mouth) symptoms, making it underdiagnosed. Systemic lupus erythematosus causes neuropathy in 5–10% of patients via vasculitis or antiphospholipid antibody-related ischemia.

These inflammatory neuropathies are important to identify because they respond to immunosuppressive treatment (glucocorticoids, IVIG, rituximab for Sjögren’s) that would be inappropriate for non-inflammatory neuropathy. The clinical clue is asymmetric presentation, rapid progression, or systemic features (joint pain, rash, sicca symptoms, elevated ESR/CRP, positive ANA) accompanying the neuropathy.

Hereditary Neuropathies

The hereditary motor and sensory neuropathies (HMSN), most commonly Charcot-Marie-Tooth disease (CMT), represent the most prevalent inherited neuromuscular disorder at 1 in 2,500 people worldwide. CMT presents as a slowly progressive bilateral neuropathy with distal leg muscle wasting (“champagne bottle” legs), foot drop, and — critically for podiatric practice — progressive bilateral pes cavus deformity with toe clawing. CMT neuropathy is length-dependent, beginning in the feet, and is characteristically not painful despite significant nerve damage (distinguishing it from most acquired neuropathies).

The genetic diagnosis is important because CMT is autosomal dominant — 50% of first-degree relatives are affected or at risk. Family members of a newly diagnosed CMT patient should undergo genetic counseling. Nerve conduction studies distinguish CMT Type 1 (severely slowed conduction velocity below 38 m/s — demyelinating) from CMT Type 2 (normal or near-normal velocity with reduced amplitude — axonal). Treatment is entirely supportive — AFO bracing, orthotics, surgical correction of foot deformity — with no disease-modifying therapy currently available, though several are in clinical trials.

Idiopathic Peripheral Neuropathy

Despite thorough evaluation — blood work, nerve conduction studies, possibly skin biopsy and genetic testing — approximately 30–40% of peripheral neuropathy cases have no identifiable cause. These are classified as idiopathic (or “cryptogenic”) neuropathy. Many are believed to represent fruste or mild hereditary neuropathies, prediabetic neuropathy (with normal fasting glucose but impaired glucose tolerance on OGTT), or immune-mediated neuropathies too mild to meet criteria for specific syndromes.

Prediabetes-associated neuropathy is increasingly recognized — glucose intolerance (2-hour OGTT above 140mg/dL despite normal fasting glucose) can produce small fiber neuropathy before frank diabetes develops. Lifestyle intervention and weight reduction reduce neuropathy progression in prediabetic neuropathy, making OGTT testing in “idiopathic” neuropathy patients clinically valuable. The prognosis of truly idiopathic neuropathy is generally favorable — it tends to progress slowly (over years to decades), remains predominantly sensory in most patients, and rarely produces significant disability in isolation.

Recommended Products for Neuropathy Foot Pain

The Most Common Diagnostic Mistake

The most common mistake with peripheral neuropathy is assuming it’s diabetic without ruling out other treatable causes. In a diabetic patient with burning feet, the natural assumption is diabetic neuropathy — but B12 deficiency (especially in a metformin user), hypothyroidism, and concurrent Sjögren’s syndrome can all coexist with diabetes and contribute to neuropathy that won’t improve with glycemic control alone. The standard workup for peripheral neuropathy should include: HbA1c, fasting glucose and OGTT, serum B12 (and methylmalonic acid if B12 borderline), TSH, complete metabolic panel (renal and liver function), CBC, ANA, anti-SSA/SSB antibodies (Sjögren’s), and serum protein electrophoresis (SPEP, for paraproteinemic neuropathy). This panel takes one blood draw and changes management in a meaningful proportion of patients.

Red Flags Requiring Urgent Neurological Evaluation

In-Office Treatment at Balance Foot & Ankle

At Balance Foot & Ankle, we evaluate peripheral neuropathy with monofilament testing (10g Semmes-Weinstein), vibrometry, two-point discrimination, and coordinate nerve conduction studies and skin punch biopsy for small fiber neuropathy confirmation when indicated. We provide custom diabetic orthotics and therapeutic footwear for neuropathic feet, wound care for neuropathic ulcers, and referral coordination with neurology, endocrinology, and vascular surgery for comprehensive neuropathy management. Same-day appointments are available.

Book a Same-Day Appointment   (810) 206-1402

Frequently Asked Questions

Sources

1. Callaghan BC, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-534.
2. England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151-2161.
3. Wolfe GI, Barohn RJ. Cryptogenic sensory and sensorimotor polyneuropathies. Semin Neurol. 1998;18(1):105-111.
4. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657-666.
5. Molloy FM, et al. Characteristics of peripheral neuropathy in patients with primary Sjogren’s syndrome. Neurology. 1997;48(6):1572-1578.
6. Guyton GP, Mann RA. The pathogenesis and surgical management of foot deformity in Charcot-Marie-Tooth disease. Foot Ankle Clin. 2000;5(2):317-326.

Dr. Tom Biernacki, DPM

Affiliate Disclosure: This page contains affiliate links to products we recommend. If you purchase through these links, Balance Foot & Ankle may earn a small commission at no additional cost to you. We only recommend products we use with our patients.

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.